Ameliorating effect of anti-Fas ligand MAb on wasting disease in murine model of chronic colitis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 285, Issue 4 48-4, 2003, Pages

  Dan, N ^a   Kanai, T ^a   Totsuka, T ^a   Iiyama, R ^a   Yamazaki, M ^a   Sawada, T ^a   Miyata, T ^a   Yagita, H ^b   Okumura, K ^b   Watanabe, M ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Crohn's disease; Fas FasL; Murine model; Therapy

Indexed keywords

FAS LIGAND; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CHRONIC DISEASE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; ENTERITIS; FEMALE; IMMUNE RESPONSE; MACROPHAGE ACTIVATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; WASTING SYNDROME;

EID: 0141701932     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00071.2003     Document Type: Article

References (27)

1. + lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway. Proc Natl Acad Sci USA 92: 11225-11229, 1995.
2. + alpha beta T cells in SCID mice with colitis. Eur J Immunol 26: 3074-3083, 1996.
3. + T-cells from SCID mice with colitis undergo Fas-mediated apoptosis in vivo. Immunol Lett 78: 7-12, 2001.
4. Chu JL, Ramos P, Rosendorff A, Nikolic-Zugic J, Lacy E, Matsuzawa A, and Elkon KB. Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome. J Exp Med 181: 393-398, 1995.
5. Fiocchi C. Inflammatory bowel disease etiology and pathogenesis. Gastroenterology 115: 182-205, 1998.
6. Kanai T, Watanabe M, Okazawa A, Sato T, Yamazaki M, Okamoto S, Ishii H, Totsuka T, Iiyama R, Okamoto R, Ikeda M, Kurimoto M, Takeda K, Akira S, and Hibi T. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology 121: 875-888, 2001.
7. Kayagaki N, Yamaguchi N, Nagao F, Matsuo S, Maeda H, Okumura K, and Yagita H. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci USA 94: 3914-3919, 1997.
8. Kennedy NJ, Kataoka T, Tschopp J, and Budd RC. Caspase activation is required for T cell proliferation. J Exp Med 190: 1891-1896, 1999.
9. Lu B, Wang L, Medan D, Toledo D, Huang C, Chen F, Shi X, and Rojanasakul Y. Regulation of Fas (CD95)-induced apoptosis by nuclear factor-κB and tumor necrosis factor-α in macrophages. Am J Physiol Cell Physiol 283: C831-C838, 2002.
10. Merger M, Viney JL, Borojevic R, Steele-Norwood D, Zhou P, Clark DA, Riddell R, Maric R, Podack ER, and Croitoru K. Defining the roles of perforin, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine. Gut 51: 155-63, 2002.
11. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, and Suda T. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 4: 1287-1292, 1998.
12. Neurath MF, Finotto S, Fuss I, Boirivant M, Galle PR, and Strober W. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol 22: 21-26, 2001.
13. Nisihara T, Ushio Y, Higuchi H, Kayagaki N, Yamaguchi N, Soejima K, Matsuo S, Maeda H, Eda Y, Okumura K, and Yagita H. Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction. J Immunol 167: 3266-3275, 2001.
14. Orlinick JR, Vaishnaw AK, and Elkon KB. Structure and function of Fas/ Fas ligand. Int Rev Immunol 18: 293-308, 1999.
15. Pinkoski MJ, Brunner T, Green DR, and Lin T. Fas and Fas ligand in gut and liver. Am J Physiol Gastrointest Liver Physiol 278: G354-G366, 2000.
16. Podolsky DK. Inflammatory bowel disease. N Engl J Med 325: 928-937, 1991.
17. + T cells. Immunity 1: 553-562, 1994.
18. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, and van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398-1405, 1999.
19. Rescigno M, Piguet V, Valzasina B, Lens S, Zubler R, French L, Kindler V, Tschopp J, and Ricciardi-Castagnoli P. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1β, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J Exp Med 192: 1661-1668, 2000.
20. Sabelko-Downes KA, and Russell JH. The role of Fas ligand in vivo as a cause and regulator of pathogenesis. Curr Opin Immunol 12: 330-335, 2000.
21. Siegel RM, Chan FK, Chun HJ, and Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immun 1: 469-474, 2000.
22. Simpson SJ, De Jong YP, Shah SA, Comiskey M, Wang B, Spielman JA, Podack ER, Mizoguchi E, Bhan AK, and Terhorst C. Consequences of Fas-ligand and perforin expression by colon T cells in a mouse model of inflammatory bowel disease. Gastroenterology 115: 849-55, 1998.
23. Strater J, Wellisch I, Riedl S, Walczak H, Koretz K, Tandara A, Krammer PH, and Moller P. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 113: 160-167, 1997.
24. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, Dewoody KL, Schaible TF, and Rutgeerts PJ. A short term study of chimeric monoclonal antibody (cA2) to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337: 1029-1035, 1997.
25. Totsuka T, Kanai T, Iiyama R, Uraushihara K, Yamazaki M, Okamoto R, Hibi T, Tezuka K, Azuma M, Akiba H, Yagita H, Okumura K, and Watanabe M. Ameliorating effect of anti-inducible costimulator monoclonal antibody in a murine model of chronic colitis. Gastroenterology 124: 410-421, 2003.
26. + T cell-transferred SCID mice by anti-OX40L MAb administration. Am J Physiol Gastrointest Liver Physiol 284: G595-G603, 2003.
27. Zhu B, Beaudette BC, Rifkin IR, and Marshak-Rothstein A. Double mutant MRL-lpr/lpr-gld/gld cells fail to trigger lpr-graft-versus-host disease in syngeneic wild-type recipient mice, but can induce wild-type B cells to make autoantibody. Eur J Immunol 30: 1778-1784, 2000.